Molecular dynamic simulations revealed that ensartinib exhibited favorable binding to c-MET. Ensartinib was highly effective in inhibiting the kinase activity of the MET exon 14 deletion protein (IC50 = 7.9 nM). Furthermore, ensartinib potently suppressed the MET pathway and the growth of Hs746T cells that were subcutaneously implanted into mice. Most importantly, of 17 patients with 14 different types of MET exon 14 skipping mutations undergoing ensartinib treatment, 1 (6%) showed a complete response, 11 (65%) achieved a partial response, and 4 (24%) exhibited stable disease. Thus, the objective response rate (ORR) was 71% and the disease control rate (DCR) was 94%, and the ORR in MET-TKI naive patients was even higher (12/15, 80%). In 2 patients with brain metastasis without prior brain radiation, we observed one partial response in the brain, while in the other patient the brain lesions were stable for 6 months. The most frequently reported adverse events were rash, peripheral edema, and nausea; however, no fatal adverse events occurred.
再次看到恩沙替尼 |
跨越十年丨憨叔靶向轮换的感悟及思路
我们在筷子治疗九周年纪念文章《跨越九年丨憨叔靶向轮换传承和发扬 --筷子奥希替尼
egfr19突变，16个月耐药，后续该如何
2023.7月爸爸确诊肺癌晚期，全身多处骨转 脑转，基因检测egfr19突变，单用阿美11个月
[9.20更新紧急求助］K药单免，肺部大
我父亲5月30,6月20，分别使用两次K药治疗。后因为肠道免疫副反应停止了K药直到现在.
免疫治疗的副作用有何征兆？可以预防
我们常说的抗肿瘤免疫治疗，多指以PD-1/PD-L1抑制剂为代表的免疫抑制剂，通过激活患
建议收藏！肺癌ALK患者靶向药耐药后
作者：闵
ALK突变常被众多病友称为“钻石突变”，不单是由于对应的靶向药价格高昂，更
显身卡
